Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BGI Collaborates with Big Pharma on Asia’s Most Common Cancers

publication date: Feb 21, 2012
BGI, the China genomics sequencing giant, has added another project to its expanding collection of global relationships. The latest collaboration is with Asia Cancer Research Group, a not-for-profit organization comprised of global heavyweights Eli Lilly, Merck and Pfizer. ACRG is seeking to discover new treatments for Asia’s most common cancers. The organization will share its findings with the scientific community to advance treatment of these diseases. More details....

Stock Symbols: (NYSE: LLY) (NYSE: MRK) (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital